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Abstract
Objective: To assess the predictors and prevalence of HIV infection among injection drug users in highly endemic
regions along major drug trafficking routes in three Chinese provinces.
Methods: We enrolled participants using community outreach and peer referrals. uestionnaire-based interviews
provided demographic, drug use, and sexual behavior information. HIV was tested via ELISA and syphilis by RPR.
Results: Of the 689 participants, 51.8% were HIV-infected, with persons living in Guangxi having significantly lower
prevalence (16.4%) than those from Xinjiang and Yunnan (66.8% and 67.1%, respectively). Syphilis seropositivity was
noted in 5.4%. Longer duration of IDU, greater awareness of HIV transmission routes, and living in Xinjiang or Yunnan
were associated with HIV seropositivity on multivariable analysis. Independent risk factors differed between sites. In
Guangxi, being male and having a longer duration of IDU were independent risk factors for HIV infection; in Xinjiang,
older age and sharing needles and/or syringes were independent factors; in Yunnan, more frequent drug injection, greater
awareness of HIV transmission routes, and higher income were independent predictors of HIV seropositivity.
Conclusion: Prevalence rates of HIV among IDUs in China are more than two out of three in some venues. Risk factors
include longer duration of IDU and needle sharing. Also associated with HIV were factors that may indicate some success
in education in higher risk persons, such as higher knowledge. A systemic community-level intervention with respect to
evidenced-based, population-level interventions to stem the spread of HIV from IDU in China should include needle
exchange, opiate agonist-based drug treatment, condom distribution along with promotion, and advocacy for
community-based VCT with bridges to HIV preventive services and care.
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Injection drug use (IDU) represents the largest single
cause of HIV transmission in China, accounting for nearly
half of the infections at the end of 2005 [1]. Ministry of
Public Security data suggest that the number of registered
drug users has risen steadily at a rate of about 122% per
year, from 70,000 in 1990 to 1.16 million in 2005 [2-4].
The total number, including unregistered drug users, is
thought to be much higher, perhaps 3.5 million [5].
China has the second largest estimate (midpoint: 1.9 mil-
lion) of IDUs worldwide, following only Russia [6]. The
first large outbreak of HIV in China was identified in 1989
among injection drug users (IDUs) in Dehong Prefecture
of Yunnan Province on the Myanmar (Burma) border in
southwest China [7]. The specific HIV subtypes first seen
in Dehong spread along drug trafficking routes to IDUs in
nearby cities in Yunnan [8,9]. Since then, serious epidem-
ics among IDUs have been identified in Xinjiang (1996),
Guangxi and Sichuan (1997), Guangdong (1998), Gansu
(1999), and Jiangxi (2000) [10]. The HIV epidemic routes
coincided with the major drug trafficking roads from the
"Golden Triangle" into China. Molecular epidemiology
suggests that the major spread of the initial drug-related
epidemic in China started in Yunnan and took two major
routes: northbound to Sichuan, Guizhou, Gansu, Ningxia
and Xinjiang, and eastbound to Guangxi, Guangdong and
Guizhou [8,9,11-18]. Before 1993, the HIV-infected cases
in China were reported mainly from Yunnan [7].
Xinjiang and Sichuan first reported HIV infections among
drug users in 1995; the HIV epidemic was first detected
among drug users in Guangxi in 1996. In subsequent
years, HIV spread rapidly among IDUs in Yunnan, Xin-
jiang, and Guangxi and by the end of 2002, all 31 prov-
inces, municipalities and autonomous regions in
mainland China, as well as Hong Kong, Macao, and Tai-
wan, had reported cases of HIV/AIDS among drug users
from 1989 to 2004. Yunnan reported the highest number
of annual HIV/AIDS cases in mainland China [7].
Yunnan's proximity to one of the world's largest illicit
drug (especially heroin) production and distribution
centers, the "Golden Triangle", contributes to drug traf-
ficking and the availability of heroin [12,19,20]. Only a
small portion of heroin/opium is trafficked into Xinjiang
from the "Golden Crescent" [3]. Currently, Yunnan, Xin-
jiang and Guangxi have remained the top three of the
hardest-hit regions fueled by IDU in China
[7,12,14,18,21-23]. However, no systematic community-
based interventions have been undertaken in these
regions. Only a small fraction of IDUs receive counseling
and testing services and even fewer have participated in
methadone maintenance treatment and needle exchange
programs that were started in 2004. Several studies have
described the different HIV transmission risk factors
among IDUs based in detoxification and detention cent-
ers in China [24,25]. However, there are few studies that
used community-based recruitment of IDUs from multi-
ple provinces [15]. A behavioral survey among drug users
in Yunnan, Xinjiang, Hubei, and Beijing found that most
of the drug users reported behaviors associated with high
rates of HIV/AIDS acquisition, such as unsafe sexual prac-
tices and using drugs intravenously (70.6%) [23]. Of
those who used drugs intravenously, 89.2% reported shar-
ing needles. The general knowledge about HIV/AIDS
among this group was relatively poor. In order to under-
stand the threat of HIV epidemic expansion and guide
appropriate HIV prevention among IDUs in three highly
endemic regions along drug trafficking routes in China,
we conducted this community-based survey to assess the




This study was conducted in three sites along major drug
(heroin) trafficking routes in Nanning City, Guangxi
Zhuang Autonomous Region; Yili Prefecture, Xinjiang
Uygar Autonomous Region; and Honghe Prefecture, Yun-
nan Province (Fig. 1). We chose these three drug traffick-
ing routes/provinces because HIV epidemics in these areas
shared certain characteristics. All three regions were hard-
est hit by HIV, IDU has been the predominant route of
transmission for HIV, and non-Han minority ethnic
groups account for a large portion of the IDUs. Most of
these IDUs live in relatively poor socioeconomic condi-
tions. Guangxi, located along the major drug trafficking
trade route bordering Yunnan on the west and Vietnam
on the southwest, hosts 49 million people. Nanning is
Guangxi's capital city and has a population of almost 2
million, 36% of whom belong to Zhuang ethnic and
other non-Han minority ethnic groups. Xinjiang covers a
very large area, with 19 million people in far northwestern
China, and has the longest boundary in China. From the
northeast to the southwest, Xinjiang borders eight coun-
tries: Mongolia, Russia, Kazakhstan, Kirghizstan,
Tajikistan, Afghanistan, Pakistan, and India. Yili Prefec-
ture, located in the northwest of Xinjiang, hosts 2 million
people: 45.2% Han, 25.4% Kazak, 15.9% Uygar, and
13.5% belong to other minorities. Yunnan is located in
southwestern China and borders Myanmar, Laos, and
Vietnam. Ethnic minorities account for 33.4% of Yun-
nan's population of 43 million. Honghe Prefecture is
located in the south of Yunnan Province. The population
of Honghe is about 4.1 million and 40.0% belong to Hani
and Yi ethnic groups, while 14.7% belong to other non-
Han minorities.Page 2 of 11
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Community-based surveys were completed from Novem-
ber 2004 to January 2005. The size of the IDU population
was estimated in each community and geographic map-
ping was conducted for each site in the study's targeted
communities. The participants were primarily enrolled by
the trained staff using community outreach and peer refer-
ral "snowball" techniques. The peer referrals were limited
to a maximum of five participants in order to enroll a rel-
atively representative sample in the IDU community. Eli-
gibility criteria required that participants be ≥18 years old
and have injected drugs at least one time in the last three
months. Blood was collected for HIV and syphilis testing.
All eligible participants were provided with risk reduction
and coping counseling, both pre- and post-test. Written
informed consent was received for all participants. Survey
information was collected anonymously and remained
confidential. The surveys also served as part of ongoing
comprehensive IDU-focused surveillance activity, com-
bining behavioral and biological information [26]. The
study was approved by the Institutional Review Board
(IRB) of the National Center for AIDS/STD Control and
Prevention of the China Centers for Disease Control and
Prevention, as well as the IRB of Vanderbilt University.
Location of study sitesFigure 1
Location of study sites. This study was conducted in three sites along major drug (heroin) trafficking routes in Yili Prefec-
ture, Xinjiang Uygar Autonomous Region (A); Honghe Autonomous Prefecture, Yunnan Province (B), and Nanning City, 
Guangxi Zhuang Autonomous Region (C).
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Participants were recruited and completed all study proce-
dures in either Chinese and/or the local language. All
interviews were conducted by trained staff in both Chi-
nese and the local languages to provide information
including (Table 1 and 2): (1) demographic characteris-
tics, e.g., sex, age, marital status, residency, ethnicity, years
of education, monthly income, and study site; (2) drug
use behaviors, e.g., duration of drug use, frequency of
injecting drugs in the last week, ever shared needle and/or
syringe during injection, the number of people shared
needle and/or syringe with in the last injection, frequency
of shared injection needle and/or syringe in the last six
months, always carried a needle and syringe when out,
and how many times a needle and syringe was used before
trashing it; and (3) sexual behaviors, e.g., living with reg-
ular sex partners in the last year, ever had sex with regular
sex partner in the last year, condom use with regulars sex
partners in the last sex act, frequency of condom use with
regular sex partners in the last year, regular sex partners
ever used drugs, regular sex partners knew you used drugs,
shared needle and/or syringe with regular sex partners,
ever had sex with non-regular sex partners in the last year,
the number of non-regular sex partners in the last year,
condom use with non-regular sex partners in the last sex
act, frequency of condom use with non-regular sex part-
ners in the last year, ever paid money or provided drugs
for sex in the last year, the number of sex partners paid or
provided drugs for sex in the last year, condom use during
paid or provided drugs for sex in the last sex act, frequency
of condom use during paid or provided drugs for sex in
the last year, ever provided sex for money or drugs for sex
in the last year, the number of sex partners who had sex
for money or drugs in the last year, condom use during sex
for money or drugs in the last sex act, and frequency of
condom use during sex for money or drugs in the last year.
Knowledge about risk of HIV transmission routes was
assessed by correctly answering five questions that were
related to modes of HIV transmission (blood, sex, and
mother to infant). The participants were further asked
whether they had ever received voluntary HIV counseling
and testing (VCT). All of the above questions in the ques-
tionnaire were selected by a panel of consultants of the
national behavioral and biological sentinel surveillance in
China [26,27].
All collected serospecimens were stored at the Prefecture-
level CDC laboratories and transported to Provincial-level
CDC for HIV testing. Two Enzyme-Linked ImmunoSorb-
ent Assays (ELISA, Vironostika HIV Uni-form II plus O™,
BioMérieux, Marcy L'Etoile, France; Beijing Wantai Bio-
logic Medicine Co., China) were performed. Both samples
testing positive were considered HIV-positive; both sam-
ples testing negative were considered HIV-negative. A
repeat second ELISA was used as a tiebreaker for discord-
ant results. Western blot confirmation of cases was possi-
ble in one province consistently, one province
intermittently, but was not used in the third province.
Syphilis serostatus was determined by screening for the
antibody to Treponema pallidum antigen (p15, p17, and
p47) and by a positive rapid-plasma reagin (RPR) test
(Macro-Vue RPR™ Card Test, Becton-Dickinson, USA).
Statistical analysis
Data were entered with EpiData. After corrections, data
were then converted and analyzed using the Statistical
Package for the Social Sciences (SPSS 15 for Windows™;
SPSS Inc., Chicago, Il, USA). The data were analyzed using
unadjusted odds ratios with 95% confidence intervals for
the odds ratio point estimates. Tests for significance of cat-
egorical data used a Chi-square test or Fisher's exact test. A
multivariable logistic regression model was constructed
with all variables in the univariate model whose p value
was less than 0.2. Thus, we report independent risk factors
for HIV infection, controlling for confounding and inter-
action from other putative risk factors.
Table 1: Demographic factors associated with HIV infection 
among injection drug users in three highly endemic regions of 
China
Factors N* % (HIV+)† OR (95% CI) P
Sex
Female 122 34.4(42) 1.0 <0.001
Male 560 55.4(310) 2.4(1.6–3.6)
Age
<30 years 234 462(108) 1.0 0.3
≥ 30 years 353 50.4(178) 1.2(0.9–1.7)
Marital status
Married 195 51.8(101) 1.0 0.06
Single 395 49.1(194) 0.9(0.7–1.3) 0.5
Separated 80 63.8(51) 1.6(1.0–2.8) 0.05
Residency
Local 658 52.7(347) 1.0 0.005
Other province 17 11.8(2) 0.1(0.03–0.5)
Ethnicity
Han 390 48.7(190) 1.0 0.03
Other 285 57.2(163) 1.4(1.0–1.9)
Years of education
>6 years 487 52.2(254) 1.0 1.0
≤ 6 years 186 52.2(97) 1.0(0.7–1.4)
Monthly income
≤ 300 Yuan 220 50.9(112) 1.0 0.08
>300 Yuan 260 58.8(153) 1.4(1.0–2.0)
District
Nanning, Guangxi 207 16.4(34) 1.0 <0.001
Yili, Xinjiang 205 66.8(137) 10.3(6.4–16.4) <0.001
Honghe, Yunnan 277 67.1(186) 10.4(6.7–16.2) <0.001
*: Total N may not equal 689, because of missing data; N: the number 
of participants being tested; †: %: the prevalence of HIV infection; 
HIV+: the number of HIV positive.Page 4 of 11
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Factors N* % (HIV+)† OR (95% CI) P
Knowledge of three major transmission routes for HIV
Yes 548 53.8 (295) 1.0 0.006
No 129 40.3 (52) 0.6 (0.4–0.9)
Received voluntary counseling and testing
No 628 51.3 (322) 1.0 0.03
Yes 34 70.6 (24) 2.5 (1.2–5.0)
Drug use behaviors
Duration of drug use (injection plus non-injection)
<5 years 114 37.7 (43) 1.0 0.002
≥ 5 years 432 53.9 (233) 1.9 (1.3–3.0)
Duration of injection drug use
<5 years 186 34.9 (65) 1.0 0.001
≥ 5 years 381 56.7 (216) 2.4 (1.7–3.5)
Frequency of drug injection in the last week
<2 times 470 53.8 (253) 1.0 0.6
≥ 2 times 176 51.7 (91) 0.9 (0.6–1.3)
Ever shared needle and/or syringe during injection
No 328 49.4 (162) 1.0 0.2
Yes 341 54.8 (187) 1.2 (0.9–1.7)
Ever shared needle and/or syringe in the last injection
No 586 51.2 (300) 1.0 0.1
Yes 78 60.3 (47) 1.4 (0.9–2.3)
No. of people shared needle and/or syringe in the last injection
= 1 19 47.4(19) 1.0 0.3
>1 56 62.5(35) 1.8(0.6–5.3)
Frequency of shared injection needle and/or syringe in the last 6 months
Never 516 52.3(516) 1.0 0.4
Sometimes 137 51.8(137) 1.0(0.7–1.4) 0.9
Always 6 83.3(5) 4.6(0.5–39.3) 0.2
Always carried a needle and syringe with you when you were out
Yes 171 53.8(92) 1.0 0.4
No 409 57.5(235) 1.2(0.8–1.7)
How many times a needle and syringe was used before trashing it
1 times 252 59.1(149) 1.0
2 times 194 56.7(110) 0.9(0.6–1.3) 0.7
>2 times 105 48.6(51) 0.7(0.4–1.0) 0.08
Sexual behavior
Living with regular sex partners in the last year
Yes 282 51.8 (146) 1.0 0.8
No 380 52.9 (201) 1.0(0.8–1.4)
Ever had sex with regular sex partners in the last year
Yes 257 51.8(133) 1.0 0.8
No 23 52.2(12) 1.0 (0.4–2.4)
Condom use with regular partner in the last sex act
Yes 76 52.6(40) 1.0 0.8
No 186 51.1(95) 0.9(0.6–1.6)
Frequency of condom use with regular sex partner in the last year
Always 81 45.7 (37) 1.0 0.4
Sometimes 146 54.8 (80) 1.4(0.8–2.5) 0.2
Never 32 53.1 (17) 1.3(0.6–3.1) 0.5
Regular sex partners ever used drugs
No 199 49.7 (99) 1.0 0.6
Yes 95 52.6 (50) 1.1 (0.7–1.8)
Regular sex partner knew you used drugs
No 81 48.1(39) 1.0 0.6
Yes 214 51.4(110) 1.1(0.7–1.9)
Ever shared needle and/or syringe with a regular sex partner
No 47 53.2(25) 1.0 0.9
Yes 46 54.3(25) 1.0(0.5–2.4)Page 5 of 11
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Socio-demographic characteristics
We included 689 eligible participants (95.4%) for the
analyses; 33 persons were excluded because of refusing to
participate or not meeting eligibility criteria. Of the partic-
ipants, 82.0% were males; 53.8% were of the majority
Han ethnicity; 72.4% had <6 years of education; and
59.0% were single, 29.1% married, and 11.9% separated
(Table 1). Their average age was 30.8 years old (S.D. ± 6.0)
and 40.0% were under 30 years old; 97.5% were local res-
idents; and 54.2% had ≤ 300 Yuan monthly incomes
(Table 1).
HIV knowledge and VCT
Of the participants, 80.9% were aware of all three trans-
mission routes (blood, sex, and mother-to-child); only
5.1% of the participants had ever received VCT (Table 2).
Drug use and sexual behaviors
Of the participants, 79.1% had used illicit drugs >5 years;
79.1% injected drugs for ≥ 5 years; and 51.0% reported a
history of sharing needles and/or syringes. To judge cur-
rent users, we determined that 27.2% had injected drugs
more than twice in the prior week. Of the 11.7% partici-
pants who reported using a shared needle and/or syringe
in the last injection, three-quarters of them shared with
Ever had sex with non-regular partners in the last year
No 528 53.4 (282) 1.0 0.3
Yes 132 48.5 (64) 0.8 (0.6–1.2)
No. of non-regular sex partners in the last year
1 45 51.1(23) 1.0 0.5
>1 56 44.6(25) 0.8(0.4–1.7)
Condom use with non-regular sex partner in the last sex act
Yes 42 54.8(23) 1.0 0.3
No 92 45.7(42) 0.7(0.3–1.4)
Frequency of condom use with non-regular sex partners in the last year
Always 73 39.7 (29) 1.0 0.1
Sometimes 36 58.3 (21) 2.1(0.9–4.8) 0.1
Never 24 58.3 (14) 2.1(0.8–5.4) 0.2
Ever paid or provided drugs for sex in the last year
No 507 56.2(507) 0.2
Yes 41 43.9(41) 0.6(0.3–1.2)
No. of sex partners ever paid or provided drugs for sex in the last year
1 10 50.0(5) 1.0 0.8
>1 24 45.8(11) 0.8(0.2–3.7)
Condom use during paid or provided drugs for sex in the last sex act
Yes 13 53.8(7) 1 0.3
No 28 39.3(11) 0.4(0.1–1.8)
Frequency of condom use during paid or provided drugs for sex in the last year
Always 5 60.0(3) 1 0.2
Sometimes 12 66.7(8) 0.4(0.2–11.5) 1
Never 23 30.4(7) 0.1(0.04–2.1) 0.3
Ever provided sex for money or drugs in the last year
No 83 32.4(27) 0.7
Yes 34 38.7(13) 1.2(0.6–2.9)
No. of sex partners for money or drugs in the last year
1 0 0 -
>1 19 36.8(8) -
Condom use during sex for money or drugs in the sex act
Yes 13 30.8(4) 0.7
No 16 43.8(7) 1.8(0.4–8.1)
Frequency of condom use during sex for money or drugs in the last year
Always 0 0 -
Sometimes 5 60.0(3) -
Never 7 14.3(1) -
Syphilis sero-status
Negative 614 50.0(307) 1.0 0.9
Positive 33 48.5(16) 0.9(0.5–1.9)
*: Total N may not equal 689, because of missing data; N: the number of participants being tested for HIV; †: %: the prevalence of HIV infection; 
HIV+: the number of HIV positive.
Table 2: Factors associated with HIV infection among injection drug users in three highly endemic regions of China (Continued)Page 6 of 11
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reported never carrying a needle and syringe when they
were out. 54.3% of the participants reported used a needle
and syringe more than once before trashing it. One-fifth
of participants reportedly had sex with non-regular part-
ners in the last year. One-third of subjects reported always
using condoms when having sex with their regular partner
in the last year, while 40.0% reported always using con-
doms when having sex with non-regular sex partners in
the last year. Over the last year, 7.5% had paid money or
provided drugs for sex and only 12.5% of them reported
using condoms consistently. 29.1% provided sex for
money or drugs and none of them reported using con-
doms consistently (Table 2).
Prevalence of syphilis seropositivity and predictors for HIV 
seropositivity
Of the 689 participants, 5.4% were RPR reactive for syph-
ilis. 51.8% were HIV-seropositive, with persons living in
Guangxi having significantly lower prevalence (16.4%)
than those from Xinjiang and Yunnan (66.8% and 67.1%,
respectively). In univariate analyses, risk factors associated
with HIV sero-positive status included male sex, "sepa-
rated" marital status, local residency, minority (i.e., non-
Han) ethnicity, study site (Yili, Xinjiang and Honghe,
Yunnan), awareness of HIV transmission routes, having
received VCT, longer duration of drug use, and longer
duration of IDU (Table 1 and 2). Sexually-related factors,
age, years of education, and syphilis seropositivity were
not associated significantly with HIV seropositive status.
Multivariable logistic regression analyses suggested that a
longer duration of IDU (Adjusted OR = 3.5; 95%CI: 1.4–
8.5), greater awareness of HIV transmission routes (AOR
= 2.0; 95%CI: 1.0–3.3), and living in Yili, Xijiang (AOR =
7.7; 95%CI: 4.4–13.4) and Honghe, Yunnan (AOR = 15.1;
95%CI: 7.2–31.7) versus in Nanning, Guangxi, were inde-
pendent risk factors for HIV sero-positivity for the three
sites (Table 3). In Nanning, Guangxi, being male (AOR =
3.3; 95%CI: 1.1–10.2) and having a longer duration of
IDU (AOR = 4.5; 95%CI: 1.3–15.6) were independent risk
factors for HIV sero-positive. In Yili, Xinjiang, older age
(AOR = 3.7; 95%CI: 1.2–11.8) and ever sharing of needles
and/or syringes (AOR = 5.7; 95% CI: 1.1–29.1) were inde-
pendent risk factors for HIV sero-positive. In Honghe,
Yunnan, higher frequency of drug injection (AOR = 3.7;
95%CI: 1.5–8.7), greater awareness of HIV transmission
routes (AOR = 2.5; 95%CI: 1.0–6.0), and higher income
(AOR = 1.8; 95% CI: 1.0–3.4) were independent risk fac-
tors for HIV sero-positive status.
Discussion
We assessed the prevalence and predictors of HIV sero-
positive among 689 IDUs with serious illicit drug prob-
lems in China using community-based cross sectional sur-
veys with consistent sampling procedures in all three
provinces (or autonomous regions). HIV prevalence was
very high (51.8%), but was lower in persons living in
Guangxi (16.4%) compared to Xinjiang and Yunnan
(67.8%). The HIV prevalence rates were remarkably simi-
lar to those from the same sites among IDUs from detoxi-
fication or detention centers [22], and were significantly
higher than estimates from community-based surveys in
other regions in China [27].
Lower rates are reported in other provinces. For example,
in January 2005, HIV prevalence rates of 0% to 5.9% were
reported in six community-based surveys of 1,260 IDUs in
Guangxi and Yunnan's adjacent provinces of Sichuan
(3.7%), Guangdong (5.9%), and Guizhou (0%), with
Table 3: Factors associated with HIV infection among injection drug users in three highly endemic regions of China, as predicted by a 
multivariable logistic regression model
Factors AOR (95% CI) P
Three sites
Duration of injection drug use: ≥ 5 years versus <5 years 3.5 (1.4–8.5) <0.01
Awareness of HIV transmission: awareness vs. unawareness 2.0 (1.0–3.3) <0.05
Yili Prefecture, Xinjiang: vs. Nanning, Guangxi 7.7 (4.4–13.4) <0.001
Honghe Prefecture, Yunnan: vs. Nanning, Guangxi 15.1 (7.2–31.7) <0.001
Site 1, Nanning, Guangxi
Duration of injection drug use: ≥ 5 years vs. <5 years 4.5 (1.3–15.6) 0.02
Sex: Male vs. female 3.3 (1.1–10.2) 0.04
Site 2, Yili, Xinjiang
Shared injection needle and/or syringe: Yes vs. No 5.7 (1.1–29.1) 0.04
Age: ≥ 30 years old vs. <30 years old 3.7 (1.2–11.8) 0.03
Site 3, Honghe, Yunnan
Frequent drug injection: 0–1 time/week vs. ≥ 2 times/week 3.7 (1.5–8.7) <0.001
Awareness of HIV transmission: awareness vs. unawareness 2.5 (1.0–6.0) 0.05
Monthly income: ≥ 300 Yuan vs. <300 Yuan 1.8 (1.0–3.4) <0.05
AOR = Adjusted Odds RatioPage 7 of 11
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Henan (0%), and Hubei (0%), provinces located farther
from Guangxi and Yunnan [27]. Higher HIV prevalence
rates among IDUs in 2004–2006 surveys are seen in those
regions of Guangxi, Xinjiang, and Yunnan where rapid
spread of the virus among drug users occurred earliest;
HIV was first reported in Yunnan in 1989 [7,22]. Overall
prevalence was noted to be 71.9% among IDUs from
detoxification centers in Honghe and Wenshan Prefec-
tures of Yunnan Province in 2000, having declined subse-
quently. One may speculate that rates have dropped due
to deaths and/or prevention successes [28]. Five out of 15
prefectures in Yunnan have reported high HIV prevalence
rates among IDUs, ranging from 48.9% to 75.0%
[7,22,29]. Biological sentinel surveillance data show that
HIV prevalence rates have reached 75.0% in certain sites
of Xinjiang and 51.0% in certain sites of Guangxi in 2005
[22]. The majority of the participants in sentinel surveil-
lance were recruited from detoxification or detention
centers and they are likely to be higher risk injectors than
IDUs in community settings. These differences could also
reflect the availability of proactive testing in the detoxifi-
cation or detention centers rather than a proven difference
between the sub-group and a wider population of IDUs.
High HIV prevalence among IDUs, prevalent needle shar-
ing and high frequency of injecting practices suggest an
urgent need to improve drug addiction treatment and risk
reduction measures in China. We found that 51.0% of the
participants had shared needles and/or syringes and
27.2% had injected drugs more than twice in the last
week. An HIV epidemic becomes self-perpetuating
(endemic) and even a modest level of risk behavior can
lead to a substantial rate of infection in the face of efficient
needle/blood transmission [30,31]. Because they live
along major drug trafficking routes, many of the HIV-
infected IDUs in our survey will continue to serve as a
major source for continued transmission and further
spread unless drug abuse treatment, antiretroviral ther-
apy, and risk reduction are implemented, as indi-
cated[32].
While longer duration of IDU, shared injection needle
and/or syringe, and higher frequency of injection were the
independent risk factors for HIV infection [14,15,33,34],
greater awareness of HIV was associated (unexpectedly)
with higher HIV prevalence. This may suggest some suc-
cesses in educating IDUs. Higher income was also a risk
factor. We speculate that drug users with higher incomes
may use drugs more often; they may also have a greater
awareness of HIV issues. There was some diversity in asso-
ciated risk factors among the IDU subgroups in the three
regions where HIV prevalence was especially high.
Although a high portion of participants know HIV trans-
mission routes in all three sites, the needle sharing rates
and unprotected sexual behaviors were still high among
IDUs. Most astonishingly, a very small portion (overall
5.1%) of participants reported ever receiving VCT, a gate-
way for the prevention programs. This indicated that a
large proportion of IDUs who have been infected with
HIV don't know their status and could continue to spread
the virus [26,35]. China has scaled up HIV control efforts
since 2004 [35]; however, low HIV testing rates (≈20%
nationwide) remain an impediment to prevention and
care. Lack of affordable accessibility to sterile needles and
syringes was the major reason for high risk sharing of
"works" in this study. Other data suggested social norms
that foster stigma, discrimination associated with drug use
and HIV/AIDS, fear of arrest due to illegal practice, know-
ing a positive result, a lack of coping skills, and knowledge
of HIV risks are the other reasons for the low rate of HIV
testing among IDUs [4,26]. This suggested that risk reduc-
tion education alone cannot help drug users and their sex
partners make lasting behavioral changes. The commu-
nity-based needle exchange programs and elimination of
any barriers to accessing clean needles and syringes could
reduce the prevalence of needle sharing among
IDUs[36,37]. In addition to providing accurate and up-to-
date information on risky behaviors, effective commu-
nity-based prevention programs not only make clean nee-
dles and condoms available and accessible, but also focus
on enhancing individuals' motivation to change their
behavioral patterns, teaching concrete strategies, and
behavioral skills to reduce risk, providing tools for risk
reduction, and reinforcing positive behavior change.
We found that there were significant differences between
sex, age, marital status, residency, ethnicity, education
level, and monthly income among the participants in the
three study sites. A larger portion of participants who were
single and belong to the Han ethnic group, with >6 years
of education and higher income, were recruited in
Honghe, Yunnan than in the other two sites. Yili, Xijiang's
participants were more likely to be younger, belong to
non-Han ethnic groups (86.9% Wei ethnic group in Yili,
Xijiang; 11.2% Hani and Yi ethnic groups in Honghe,
Yunnan and 32.2% Zhuang ethnic group in Nanning,
Guangxi), and receive lower levels of education. Nanning,
Guangxi's participants were more likely to have less
monthly income (74.2% with ≤ 300 Yuan RMB monthly
income). We found that higher income in Honghe, being
male in Nanning, and old age in Yili were independently
associated with HIV infection. There could be other fac-
tors beyond this study, besides gender, age and the shar-
ing of needles, such as the actual availability of syringe
distribution and exchange programs, condom distribu-
tion and promotion, and other social determinants of
health that account for the differences for the HIV preva-
lence rates in the three study sites. China's central govern-
ment has scaled up HIV/AIDS control efforts since 2004Page 8 of 11
(page number not for citation purposes)
Harm Reduction Journal 2008, 5:29 http://www.harmreductionjournal.com/content/5/1/29[35], including setting up national policy framework for
responding to HIV/AIDS, increasing funding inputs, and
expanding collaborations with international organiza-
tions. However, responses to drug use and the HIV/AIDS
epidemic vary significantly at provincial and lower
administrative levels. A literature review indicated that
Yunnan and Guangxi provinces have done far more than
other provinces in supporting, implementing, and advo-
cating for harm reduction interventions for IDUs [4].
Some local governments are not fully motivated to con-
front drug abuse and HIV/AIDS problems [4].
Among IDUs in other studies from China, risky sexual
behaviors have been reported as a risk factor for HIV infec-
tion [14,15,34], although we did not find this association
in our three populations. Most of our participants that
lived in remote rural areas of Honghe, Yunnan and Yili,
Xinjiang were less likely to receive health education and
services. Furthermore, due to relatively poor economic
status and lower levels of education, they may be more
likely to be involved in drug smuggling and abuse, and
unprotected sexual behavior. Risk reduction programs
should give high priority to these poorer, more isolated
IDUs who are also more likely to be of minority ethnic
origin. Because of the high prevalence of HIV and often
risky sexual behavior among IDUs, there is a great poten-
tial for IDUs serving as a bridge population to transmit
HIV to the general population. The overlapping of risk
behaviors among at-risk persons facilitates the rapid HIV
spread from IDUs to other risk groups, e.g., from female
sex workers and their clients to their clients' regular part-
ners. We found that low condom use rates and the high
proportion of female drug users who had reported engag-
ing in commercial sex underscore the importance of
behavioral surveillance in IDUs to provide early warnings
and more effective interventions. This highlighted the
need for condom distribution and promotion. As noted in
this study, most of the target IDUs interviewed already
knew the causes of HIV; the problem is not knowledge
translation, it is more basic social determinants of health.
They don't have access to free condoms. Free condoms
should be provided widely to sex trade workers and IDUs.
The prevalence of syphilis by RPR in our high risk IDUs
was 5.4% (33/647), similar to estimates in 10 sentinel
surveillance sites using RPR screening in 1,414 IDUs in
the same three provinces (average: 6.6%, range from 1.2
to 14.1%) [22]. Syphilis seropositivity did not predict
HIV, suggesting that most infections were due to injec-
tion-related behaviors. Other studies have reported an
association between HIV infection and other STDs among
IDUs [38-41]. Syphilis should be considered one indica-
tor of high sexual risk behavior among IDUs [42]. Previ-
ous studies of syphilis among IDUs have suggested that
while a high prevalence of syphilis and low HIV preva-
lence may be found in clinical or community settings, the
reverse pattern of high HIV prevalence and low prevalence
of syphilis may be more common in detoxification centers
where IDUs, who are heavier drug users, are overrepre-
sented [22,43]. The patterns of STD co-morbidity among
IDUs vary significantly by venue and high risk group
[22,44].
Strengths of this study include its substantial sample size,
the geographic diversity of our venues, and community-
based outreach and peer referral using "snowball" and
mapping strategies. There are also limitations. First, IDUs
recruited into the study may have been higher risk such
that their HIV prevalence may not exactly reflect the true
background rate among IDUs in the study community.
Second, recall bias and social desirability bias are possi-
ble, since the drug use and sexual behavioral information
was collected based on self-reporting. Most information
about drug use and sexual behaviors in the last year were
used in the data collection, instead of collecting the
behaviors in more recent period, in the last three or six
months. Third, our cross-sectional study cannot ascertain
a causal association between predictors and HIV infec-
tions. Fourth, we do not include a complete list of factors
in this study. Other factors beyond this study may also
account for the differences.
China has initiated harm reduction projects, including
needle exchange programs, methadone treatment, con-
dom promotion, and VCT programs among drug users
[4,25,36,37,45,46]. China Center for Disease Control and
Prevention provincial authorities have been organizing
the needle exchange and methadone treatments since
early 2004 [20,46,47]. China plans to scale up harm
reduction projects, including needle exchange programs
and methadone treatments, since only a small portion of
IDUs have been covered by these programs so far. Our
data suggest the urgent need for expanded community-
level needle exchange programs, opiate agonist-based
drug treatment, and advocacy for community-based VCT
with bridges to HIV preventive services and care. Condom
distribution along with condom promotion should also
be highlighted. In vulnerable target populations where
condom use is directly related to availability, condom dis-
tribution and promotion is crucial to helping curb the
spread of HIV and other STDs. These prevention and treat-
ment efforts are likely to require an infrastructure that not
only provides operational and financial support, but also
creates an environment in which IDUs feel comfortable
and safe in seeking help without any barriers. Implemen-
tation research programs can critically assess these pro-
grams and provide insight as to where they might be
improved.Page 9 of 11
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